Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.24. On average, analysts expect Corbus Pharmaceuticals to post $-4 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Corbus Pharmaceuticals Trading Up 3.6 %

Corbus Pharmaceuticals stock opened at $7.79 on Friday. The company’s 50-day moving average price is $6.39 and its two-hundred day moving average price is $11.20. The stock has a market cap of $95.29 million, a price-to-earnings ratio of -1.66 and a beta of 3.19. Corbus Pharmaceuticals has a 52 week low of $4.64 and a 52 week high of $61.90.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wedbush reissued an “outperform” rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective (down previously from $75.00) on shares of Corbus Pharmaceuticals in a report on Wednesday, March 12th. StockNews.com raised Corbus Pharmaceuticals to a “sell” rating in a research note on Thursday, March 6th. William Blair initiated coverage on shares of Corbus Pharmaceuticals in a research report on Friday, February 28th. They issued an “outperform” rating on the stock. Finally, Jefferies Financial Group reduced their price objective on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.13.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.